Meeting
2019 ASCO Annual Meeting
De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.
Authors
Hadar Goldvaser
Rabin Medical Center, Beilinson Hospital, Davidoff Center, Kyriat Ono, Israel
Hadar Goldvaser , Korzets Ceder Yasmin , Daniel Shepshelovich , Rinat Yerushalmi , Michal Sarfaty , Domen Ribnikar , Paaladinesh Thavendiranathan , Eitan Amir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 524)
DOI
10.1200/JCO.2019.37.15_suppl.524
Abstract #
524
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.
First Author: Paul Stewart
Poster
2023 ASCO Annual Meeting
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
First Author: Anna-Maria Lazaratos
Poster
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
First Author: Naomi RM Schwartz
Poster
2016 ASCO Annual Meeting
Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.
First Author: Shruti Rakesh Tiwari